X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-04 | MGNX | Peters Jeffrey Stuart | SVP, GC | S - Sale+OE | $15.55 | -51,395 | 0 | -100% | -$799,148 | |||||
| D | 2024-03-06 | MGNX | Peters Jeffrey Stuart | SVP, GC | S - Sale+OE | $21.50 | -19,625 | 8,895 | -69% | -$421,938 | |||||
| D | 2024-03-04 | MGNX | Risser Eric Blasius | COO | S - Sale+OE | $19.76 | -41,159 | 38,900 | -51% | -$813,501 | |||||
| D | 2024-03-04 | MGNX | Spitznagel Thomas | SVP, Technical Ops | S - Sale+OE | $20.00 | -10,000 | 8,316 | -55% | -$200,000 | |||||
2024-03-04 | MGNX | Karrels James | SVP, CFO, Secretary | S - Sale | $20.50 | -30,000 | 171,452 | -15% | -$615,000 | ||||||
2024-02-26 | MGNX | Peters Jeffrey Stuart | SVP, GC | S - Sale | $17.22 | -16,124 | 8,895 | -64% | -$277,655 | ||||||
2024-02-07 | MGNX | Bonvini Ezio | SVP, Research, CSO | S - Sale | $18.00 | -3,334 | 71,334 | -4% | -$60,012 | ||||||
| D | 2024-02-05 | MGNX | Peters Jeffrey Stuart | SVP, GC | S - Sale+OE | $16.50 | -76,251 | 0 | -100% | -$1,258,142 | |||||
2024-02-01 | MGNX | Bonvini Ezio | SVP, Research, CSO | S - Sale | $15.00 | -13,316 | 74,668 | -15% | -$199,740 | ||||||
2024-01-19 | MGNX | Bonvini Ezio | SVP, Research, CSO | S - Sale | $12.00 | -13,316 | 87,984 | -13% | -$159,792 | ||||||
2023-12-20 | MGNX | Bonvini Ezio | SVP, Research, CSO | S - Sale | $10.08 | -18,880 | 101,300 | -16% | -$190,310 | ||||||
2023-10-02 | MGNX | Biotech Target N V | 10% | P - Purchase | $4.46 | +150,000 | 9,929,963 | +2% | +$669,585 | ||||||
2023-09-07 | MGNX | Biotech Target N V | 10% | P - Purchase | $5.26 | +200,000 | 9,779,963 | +2% | +$1,052,840 | ||||||
2023-08-30 | MGNX | Hurwitz Edward | Dir | P - Purchase | $4.91 | +15,000 | 33,074 | +83% | +$73,650 | ||||||
2023-03-10 | MGNX | Peters Jeffrey Stuart | SVP, GC | S - Sale | $6.03 | -5,372 | 0 | -100% | -$32,393 | ||||||
2023-02-14 | MGNX | Biotech Target N V | 10% | P - Purchase | $5.07 | +500,000 | 9,579,963 | +6% | +$2,532,600 | ||||||
2023-01-19 | MGNX | Biotech Target N V | 10% | P - Purchase | $5.30 | +150,000 | 9,079,963 | +2% | +$794,925 | ||||||
| M | 2022-12-23 | MGNX | Biotech Target N V | 10% | P - Purchase | $5.75 | +400,000 | 8,929,963 | +5% | +$2,298,600 | |||||
2022-11-22 | MGNX | Biotech Target N V | 10% | P - Purchase | $5.96 | +300,000 | 8,529,963 | +4% | +$1,788,180 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |